Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Systemic lupus erythematosus (SLE) is characterized by multisystemic clinical manifestations ranging from a relatively mild involvement to potentially life-threatening complications. Due to this complexity, a multidisciplinary (MD) approach is the best strategy for optimizing patients' care. The main aim of this systematic literature review (SLR) was to scrutinize the published data regarding the MD approach for the management of SLE patients. The secondary objective was to evaluate the outcomes of the MD approach in SLE patients. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines were used. We performed an SLR to retrieve articles available in English or Italian listed in PubMed, Embase, Cinahl, and Cochrane Library concerning the MD approach used in observational studies and clinical trials. Four independent reviewers performed the study selection and data collection. Of 5451 abstracts evaluated, 19 studies were included in the SLR. The MD approach was most frequently described in the context of SLE pregnancy, reported in 10 papers. MD teams were composed of a rheumatologist, except for one cohort study; a gynecologist; a psychologist; a nurse; and other health professionals. MD approaches had a positive impact on pregnancy-related complications and disease flares and improved SLE psychological impact. Although international recommendations advise an MD approach for managing SLE, our review highlighted the paucity of data supporting this strategy, with most of the available evidence on the management of SLE during pregnancy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298977PMC
http://dx.doi.org/10.3390/jcm12124059DOI Listing

Publication Analysis

Top Keywords

sle
8
management sle
8
sle patients
8
sle pregnancy
8
approach
6
optimizing patient
4
patient care
4
care systematic
4
systematic review
4
review multidisciplinary
4

Similar Publications

Pharmacological insights into gut microbiota modulation in systemic lupus erythematosus: Mechanisms, treatment strategies, and clinical implications.

J Pharmacol Exp Ther

July 2025

Department of Pharmacy Practice, Parul Institute of Pharmacy & Research, Parul University, Limda, Waghodia, Vadodara, Gujarat, India. Electronic address:

Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by widespread inflammation and immune system dysregulation. Recent research suggests that the gut microbiota may play a role in the development of SLE by modulating immune system responses, affecting cytokine production, and altering the activity of T and B cells lymphocytes. As a result, there is a growing interest in microbiota-targeted therapies, including probiotics, dietary changes, and fecal microbiota transplantation.

View Article and Find Full Text PDF

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by complex disturbances in both innate and adaptive immune responses, often leading to multi-organ involvement. One of the key features of SLE pathogenesis is endothelial dysfunction, which contributes to immune cell infiltration and vascular inflammation. In this context, adhesion molecules such as platelet endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) may reflect the degree of endothelial activation.

View Article and Find Full Text PDF

Background: Pericardial involvement is common in systemic lupus erythematosus (SLE) and can lead to recurrent episodes. B cell-targeted therapies are commonly used in the treatment of SLE pericarditis. The management of recurrent lupus pericarditis refractory to B cell-targeted therapy remains challenging.

View Article and Find Full Text PDF

The present investigation elucidates the therapeutic potential of glycyrrhizin, the predominant triterpene saponin isolated from (licorice), in the management of systemic lupus erythematosus (SLE), an autoimmune disorder characterized by multisystemic involvement and therapeutic recalcitrance. Comprehensive interrogation of multiple disease-specific databases facilitated the identification of crucial SLE-associated molecular targets and hub genes, with MAPK1, MAPK3, TP53, JUN, and JAK2 demonstrating the highest degree of network centrality. Subsequent molecular docking simulations and binding affinity assessments revealed compounds with exceptional complementarity to these pivotal molecular targets, establishing as a pharmacologically promising botanical source and glycyrrhizin as its principal bioactive constituent meriting comprehensive mechanistic investigation.

View Article and Find Full Text PDF

BACKGROUND Mycophenolate mofetil (MMF) is a disease-modifying antirheumatic drug (DMARD) that has been reported to cause skin rashes. Systemic lupus erythematosus (SLE) is also associated with typical discoid skin lesions. This report describes the case of a 50-year-old woman with a 6-year history of SLE presenting with a 6-day history of fever and skin rash after starting treatment with MMF.

View Article and Find Full Text PDF